NCT00423267View on ClinicalTrials.gov

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Coccidioidomycosis
Interventions
DRUG

Posaconazole

Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months

DRUG

Fluconazole

Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00423267 - POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) | Biotech Hunter | Biotech Hunter